Nuvation Bio reports $18.5M Q1 revenue for IBTROZI and gains global rights to safusidenib for cancer treatment.

Nuvation Bio announced $18.5 million in net product revenue for IBTROZI (taletrectinib) in Q1 2026, with strong adoption among newly treated patients with advanced ROS1-positive NSCLC. The company also acquired global development and commercialization rights to safusidenib, an investigational drug for IDH1-mutant glioma, expanding its oncology portfolio. Updated clinical data showed IBTROZI's durable response and progression-free survival, supporting its growing role as a standard treatment. Nuvation Bio maintains a strong cash position of $533.7 million and plans further updates on its drug conjugate platform later in 2026.